Testosterone in women is having a clinical moment — but whether it belongs as a standard component of menopausal hormone therapy for all women remains one of the most actively debated questions in the field. Proponents point to compelling data on sexual function, mood, energy, cognitive clarity, and musculoskeletal health, and argue that testosterone has been systematically overlooked in women's health for decades. Critics raise legitimate questions about long-term safety data, the absence of FDA-approved formulations for women, dosing standardization, and the risk of overcorrecting from historical neglect into uncritical universal prescribing. In this HERmedicine Great Debates in Menopause session, expert panelists argue both sides of the question with rigor and candor: should testosterone be a standard component of MHT for all women — or does the evidence support a more individualized, selective approach? A session for clinicians ready to engage with one of menopause medicine's most consequential and unresolved debates.